» Articles » PMID: 33157144

Design and Synthesis of Novel Pyrazole-phenyl Semicarbazone Derivatives As Potential α-glucosidase Inhibitor: Kinetics and Molecular Dynamics Simulation Study

Overview
Publisher Elsevier
Date 2020 Nov 6
PMID 33157144
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A series of novel pyrazole-phenyl semicarbazone derivatives were designed, synthesized, and screened for in vitro α-glucosidase inhibitory activity. Given the importance of hydrogen bonding in promoting the α-glucosidase inhibitory activity, pharmacophore modification was established. The docking results rationalized the idea of the design. All newly synthesized compounds exhibited excellent in vitro yeast α-glucosidase inhibition (IC values in the range of 65.1-695.0 μM) even much more potent than standard drug acarbose (IC = 750.0 μM). Among them, compounds 8o displayed the most potent α-glucosidase inhibitory activity (IC = 65.1 ± 0.3 μM). Kinetic study of compound 8o revealed that it inhibited α-glucosidase in a competitive mode (Ki = 87.0 μM). Limited SAR suggested that electronic properties of substitutions have little effect on inhibitory potential of compounds. Cytotoxic studies demonstrated that the active compounds (8o, 8k, 8p, 8l, 8i, and 8a) compounds are also non-cytotoxic. The binding modes of the most potent compounds 8o, 8k, 8p, 8l and 8i was studied through in silico docking studies. Molecular dynamic simulations have been performed in order to explain the dynamic behavior and structural changes of the systems by the calculation of the root mean square deviation (RMSD) and root mean square fluctuation (RMSF).

Citing Articles

Rational design, synthesis, in vitro, and in-silico studies of pyrazole‑phthalazine hybrids as new α‑glucosidase inhibitors.

Roshan M, Mirzazadeh R, Tajmir-Riahi A, Asgari M Sci Rep. 2025; 15(1):3744.

PMID: 39885319 PMC: 11782499. DOI: 10.1038/s41598-025-87258-3.


A Captivating Potential of Schiff Bases Derivatives for Antidiabetic Activity.

Sahu R, Shah K Curr Pharm Des. 2024; 31(1):37-56.

PMID: 39313905 DOI: 10.2174/0113816128339161240913055034.


Targeting Diabetes with Azole-derived Medicinal Agents.

Mehra A Med Chem. 2024; 20(9):855-875.

PMID: 38840402 DOI: 10.2174/0115734064289990240524055002.


Structural, dynamic behaviour, in-vitro and computational investigations of Schiff's bases of 1,3-diphenyl urea derivatives against SARS-CoV-2 spike protein.

Ullah S, Ullah A, Waqas M, Ahsan Halim S, Pasha A, Shafiq Z Sci Rep. 2024; 14(1):12588.

PMID: 38822113 PMC: 11143201. DOI: 10.1038/s41598-024-63345-9.


Exploring chalcone-sulfonyl piperazine hybrids as anti-diabetes candidates: design, synthesis, biological evaluation, and molecular docking study.

Hosseini Nasab N, Raza H, Eom Y, Shah F, Kwak J, Kim S Mol Divers. 2024; 29(1):43-59.

PMID: 38775996 DOI: 10.1007/s11030-024-10831-x.